Cargando…
Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis
The efficacy and safety of incobotulinumtoxinA ≤400 U was demonstrated in subjects with post-stroke upper-limb spasticity in a randomized, double-blind Phase 3 study with an open-label extension (OLEX; EudraCT number 2005-003951-11, NCT00432666). We report a post-hoc analysis of the duration of the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862578/ https://www.ncbi.nlm.nih.gov/pubmed/33551974 http://dx.doi.org/10.3389/fneur.2020.615706 |
_version_ | 1783647315800621056 |
---|---|
author | Kaňovský, Petr Elovic, Elie P. Hanschmann, Angelika Pulte, Irena Althaus, Michael Hiersemenzel, Reinhard Marciniak, Christina |
author_facet | Kaňovský, Petr Elovic, Elie P. Hanschmann, Angelika Pulte, Irena Althaus, Michael Hiersemenzel, Reinhard Marciniak, Christina |
author_sort | Kaňovský, Petr |
collection | PubMed |
description | The efficacy and safety of incobotulinumtoxinA ≤400 U was demonstrated in subjects with post-stroke upper-limb spasticity in a randomized, double-blind Phase 3 study with an open-label extension (OLEX; EudraCT number 2005-003951-11, NCT00432666). We report a post-hoc analysis of the duration of the treatment effect. Subjects completing the placebo-controlled main period (single injection cycle with 12–20-week observation) entered the OLEX and received a maximum of five further treatments (maximum duration 69 weeks) with incobotulinumtoxinA ≤400 U at flexible intervals with a minimum duration of 12 weeks, based on clinical need. Intervals between two consecutive incobotulinumtoxinA injections, excluding treatment intervals prior to the end-of-study visit, were evaluated. Of 437 incobotulinumtoxinA treatment intervals, 415 received by 136 subjects were included in the post-hoc analysis. More than half (52.3%; 217/415) of all incobotulinumtoxinA reinjections were administered at Week ≥14, 31.1% (129/415) at Week ≥16, 19.0% (79/415) at Week ≥18, and 11.6% (48/415) at Week ≥20. The duration of effect may vary and can exceed 20 weeks or more, which was observed in at least one injection cycle in 29.4% (40/136) subjects over the course of their treatment. Data show that incobotulinumtoxinA retreatment for upper-limb spasticity may not be required at 12-week intervals and provides evidence for flexible treatment intervals beyond this time frame. |
format | Online Article Text |
id | pubmed-7862578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78625782021-02-06 Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis Kaňovský, Petr Elovic, Elie P. Hanschmann, Angelika Pulte, Irena Althaus, Michael Hiersemenzel, Reinhard Marciniak, Christina Front Neurol Neurology The efficacy and safety of incobotulinumtoxinA ≤400 U was demonstrated in subjects with post-stroke upper-limb spasticity in a randomized, double-blind Phase 3 study with an open-label extension (OLEX; EudraCT number 2005-003951-11, NCT00432666). We report a post-hoc analysis of the duration of the treatment effect. Subjects completing the placebo-controlled main period (single injection cycle with 12–20-week observation) entered the OLEX and received a maximum of five further treatments (maximum duration 69 weeks) with incobotulinumtoxinA ≤400 U at flexible intervals with a minimum duration of 12 weeks, based on clinical need. Intervals between two consecutive incobotulinumtoxinA injections, excluding treatment intervals prior to the end-of-study visit, were evaluated. Of 437 incobotulinumtoxinA treatment intervals, 415 received by 136 subjects were included in the post-hoc analysis. More than half (52.3%; 217/415) of all incobotulinumtoxinA reinjections were administered at Week ≥14, 31.1% (129/415) at Week ≥16, 19.0% (79/415) at Week ≥18, and 11.6% (48/415) at Week ≥20. The duration of effect may vary and can exceed 20 weeks or more, which was observed in at least one injection cycle in 29.4% (40/136) subjects over the course of their treatment. Data show that incobotulinumtoxinA retreatment for upper-limb spasticity may not be required at 12-week intervals and provides evidence for flexible treatment intervals beyond this time frame. Frontiers Media S.A. 2021-01-22 /pmc/articles/PMC7862578/ /pubmed/33551974 http://dx.doi.org/10.3389/fneur.2020.615706 Text en Copyright © 2021 Kaňovský, Elovic, Hanschmann, Pulte, Althaus, Hiersemenzel and Marciniak. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Kaňovský, Petr Elovic, Elie P. Hanschmann, Angelika Pulte, Irena Althaus, Michael Hiersemenzel, Reinhard Marciniak, Christina Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis |
title | Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis |
title_full | Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis |
title_fullStr | Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis |
title_full_unstemmed | Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis |
title_short | Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis |
title_sort | duration of treatment effect using incobotulinumtoxina for upper-limb spasticity: a post-hoc analysis |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862578/ https://www.ncbi.nlm.nih.gov/pubmed/33551974 http://dx.doi.org/10.3389/fneur.2020.615706 |
work_keys_str_mv | AT kanovskypetr durationoftreatmenteffectusingincobotulinumtoxinaforupperlimbspasticityaposthocanalysis AT eloviceliep durationoftreatmenteffectusingincobotulinumtoxinaforupperlimbspasticityaposthocanalysis AT hanschmannangelika durationoftreatmenteffectusingincobotulinumtoxinaforupperlimbspasticityaposthocanalysis AT pulteirena durationoftreatmenteffectusingincobotulinumtoxinaforupperlimbspasticityaposthocanalysis AT althausmichael durationoftreatmenteffectusingincobotulinumtoxinaforupperlimbspasticityaposthocanalysis AT hiersemenzelreinhard durationoftreatmenteffectusingincobotulinumtoxinaforupperlimbspasticityaposthocanalysis AT marciniakchristina durationoftreatmenteffectusingincobotulinumtoxinaforupperlimbspasticityaposthocanalysis |